Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.

Author: BakerShawna, CampbellRichard, CannonDaniel C, CaprihanArvind, GonzalesSean, LoweJean, OhlsRobin K, PatelShrena, PhillipsJohn, SteffenMichael, WiedmeierSusan, WinterSarah, YeoRonald A

Paper Details 
Original Abstract of the Article :
BACKGROUND: We previously reported improved neurodevelopmental outcomes at 2 years among infants treated with the erythropoiesis-stimulating agents (ESAs) darbepoetin alfa (darbepoetin) or erythropoietin. Here we characterize 4-year outcomes. METHODS: Former preterm infants randomly assigned to rec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771132/

データ提供:米国国立医学図書館(NLM)

Erythropoiesis-Stimulating Agents and Preterm Infant Development: A Long-Term Study

This research, published in the journal Pediatrics, investigates the long-term neurodevelopmental outcomes of preterm infants treated with erythropoiesis-stimulating agents (ESAs). ESAs are medications used to stimulate red blood cell production, and their use in preterm infants has been a subject of ongoing research. The authors conducted a randomized controlled trial comparing the effects of darbepoetin alfa, erythropoietin, and placebo on preterm infants. Their analysis revealed that ESA-treated infants had better cognitive outcomes and less developmental impairment at 3.5 to 4 years of age compared to placebo-treated infants. These findings suggest that ESAs may have a positive impact on the long-term neurodevelopmental outcomes of preterm infants.

ESAs: A Potential Boon for Preterm Infants

This research provides evidence that ESAs may offer a potential benefit for preterm infants, contributing to improved cognitive outcomes and reduced developmental impairment. The study highlights the importance of ongoing research to better understand the long-term effects of ESAs on preterm infant development and identify potential applications for improving developmental outcomes. The authors emphasize the need for careful monitoring and individualized treatment approaches to ensure the safe and effective use of ESAs in preterm infants.

Navigating the Desert of Preterm Infant Care

This research underscores the importance of ongoing research and innovation in the care of preterm infants. Just as a skilled navigator guides a caravan through the challenging desert landscape, researchers are continually seeking ways to improve the care and outcomes of preterm infants. This study offers a promising avenue for improving the long-term developmental prospects of preterm infants, highlighting the importance of utilizing evidence-based approaches to optimize care.

Dr.Camel's Conclusion

This research offers a beacon of hope in the vast and challenging desert of preterm infant care. The findings suggest that ESAs may hold the key to improving the long-term developmental outcomes of preterm infants. Just as a camel navigates the desert with resilience and determination, researchers are diligently seeking ways to improve the lives of preterm infants, paving the way for a brighter future.
Date :
  1. Date Completed 2016-07-14
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26908704

DOI: Digital Object Identifier

PMC4771132

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.